Recently, Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration and the Medical Drugs Administration jointly issued the "Biomedical New Technology Transformation and Application Implementation Catalog (Second batch)".

This is an update following the release of the first batch of catalogs in February this year, which includes 17 new cell and gene therapy technologies, and for the first time, cellular exosome technologies are included in the clinical application implementation list. The rapid release of the second batch of catalogs reflects the advantages of Hainan Free Trade Port in the field of biomedical new technology transformation and application, and provides a practical reference for the standardized development of cell and gene therapy technology in the country.

Previously, the "Directory for the Implementation of the Transformation and Application of New Biomedical Technologies (the first batch)" was released as follows:

In December last year, the Standing Committee of the Hainan Provincial People's Congress announced the "Regulations on the Promotion of New Biomedical Technologies in the Hainan Free Trade Port Boao Lecheng International Medical Tourism Pilot Zone" (hereinafter referred to as the "Regulations"), which will take effect from February 1, 2025. Among them, Article 2 of the "Provisions" points out that the clinical research, transformation and application of new biomedical technologies such as cell therapy, gene therapy and tissue engineering in the pilot area and their supervision and management activities shall be applicable to these Provisions.